Overview and Pediatric Differences

Pediatric Inflammatory Bowel Disease (IBD)—comprising Crohn Disease (CD), Ulcerative Colitis (UC), and IBD-Unclassified (IBD-U)—exhibits distinct phenotypic differences compared to adult disease. Children present with more extensive pan-enteric involvement, higher rates of stricturing/penetrating complications, and unique pediatric consequences including growth impairment, delayed puberty, and severe osteopenia.

Classification follows the Paris Classification (pediatric modification of Montreal), which incorporates age at diagnosis ($A1a < 10\text{ yr}$, $A1b\ 10–17\text{ yr}$) and explicitly tracks growth failure ($G0$ vs. $G1$).


The "Treat-to-Target" Strategy (STRIDE-II Consensus)

The Selecting Therapeutic Targets in Inflammatory Bowel Disease-II (STRIDE-II, pediatric update) established formal treatment targets to alter long-term disease course:

flowchart TD
    A["Pediatric IBD Diagnosed & Staged (Paris Classification)"] --> B["Induction of Remission:<br/>EEN for 6–8 weeks in luminal CD OR Corticosteroids / Biologics"]
    
    B --> C["Short-Term Target (Weeks 2–4):<br/>Clinical Response & Symptom Resolution<br/>(PCDAI < 10 or PUCAI < 10)"]
    
    C --> D["Intermediate Target (Weeks 8–12):<br/>Biochemical Remission<br/>Normal CRP + Normalization of Fecal Calprotectin (< 100–250 μg/g)"]
    
    D --> E["Long-Term Target (Months 6–12):<br/>1. Endoscopic Mucosal Healing (SES-CD = 0 or Mayo Score 0)<br/>2. Normalization of Linear Growth Velocity & Pubertal Staging<br/>3. Restoration of Normal Quality of Life (QoL)"]
    
    E -->|Target Achieved| F["Maintenance with TDM-guided Biologics / Immunomodulators"]
    E -->|Target Not Achieved| G["Dose Escalation via Proactive TDM OR Switch Biologic Class"]
TimeframeTarget CategorySpecific Objective Metrics
Immediate (Weeks 2–4)Clinical ResponseReduction in Paediatric Crohn's Disease Activity Index (PCDAI) by $>12.5$ points, or Paediatric Ulcerative Colitis Activity Index (PUCAI) drop by $>20$ points.
Short-Term (Weeks 8–12)Clinical & Biochemical RemissionFull clinical remission ($\text{PCDAI} < 10$, $\text{PUCAI} < 10$), normalization of serum albumin and CRP ($<5\text{ mg/L}$).
Intermediate (Months 3–6)Biomarker Mucosal RemissionFecal Calprotectin $< 100–250\ \mu\text{g/g}$ (surrogate non-invasive marker of gut healing).
Long-Term (Months 6–12)Deep Mucosal & Histological HealingAbsence of ulcerations on ileocolonoscopy (SES-CD score $= 0$ or Mayo endoscopic subscore $0–1$); histological absence of neutrophils; restoration of normal linear growth velocity (height SDS recovery).

Nutritional Induction Therapy: Exclusive Enteral Nutrition (EEN)

Clinical Protocol

  • First-Line Induction: Recommended by ECCO and ESPGHAN as the primary first-line therapy for inducing remission in mild-to-moderate luminal pediatric Crohn Disease.
  • Regimen: 100% of daily caloric and nutritional requirements administered via standard liquid polymeric formula (oral or via nasogastric tube) for 6 to 8 consecutive weeks, with total exclusion of all regular food products.
  • Efficacy vs. Corticosteroids: Achieves clinical remission rates comparable to systemic oral corticosteroids ($75–85\%$), but demonstrates superior mucosal healing ($73\%$ vs. $33\%$) and enhances bone mineral density and linear growth without steroid-induced growth stunting.
  • Maintenance Dietary Strategies: Crohn's Disease Exclusion Diet (CDED) combined with Partial Enteral Nutrition (PEN) maintains long-term remission while allowing structured reintroduction of specific whole foods.

Biologics and Advanced Targeted Therapies

flowchart LR
    A["Biologic & Small-Molecule Arsenal"] --> B["Anti-TNF Agents<br/>• Infliximab (IV, TDM-guided)<br/>• Adalimumab (SC)"]
    A --> C["Gut-Selective Anti-Integrin<br/>• Vedolizumab (anti-α4β7)"]
    A --> D["Anti-IL-12/23 Pathway<br/>• Ustekinumab (anti-p40)<br/>• Risankizumab (anti-p19)"]
    A --> E["Oral JAK Inhibitors<br/>• Upadacitinib (JAK-1 selective)<br/>• Tofacitinib"]

1. Anti-Tumor Necrosis Factor (Anti-TNF) Therapies

Biologic AgentMechanism & RegimenIndications & Pediatric Trial EvidenceProactive Therapeutic Drug Monitoring (TDM) Targets
Infliximab (Remicade / Biosimilars)Chimeric IgG1 monoclonal antibody against soluble and membrane-bound TNF-$\alpha$.
IV infusion $5–10\text{ mg/kg}$ at 0, 2, and 6 weeks (induction), then every 8 weeks (maintenance).
Indicated for moderate-to-severe CD and UC refractory to first-line agents, or as "top-down" therapy for high-risk phenotypes (perianal fistulas, deep ulcerations, severe growth stunting). REACH Trial demonstrated $>88\%$ response at week 10.Trough Level Optimization:
• Maintenance trough: $> 5–10\ \mu\text{g/mL}$.
• Perianal fistulizing CD: $> 10–15\ \mu\text{g/mL}$.
• Detect Anti-Drug Antibodies (ADA); if high ADA present, switch drug class.
Adalimumab (Humira / Biosimilars)Fully human IgG1 anti-TNF mAb.
Subcutaneous injection every 2 weeks.
Weight-tiered dosing: $80/40\text{ mg}$ or $160/80\text{ mg}$ induction, followed by $20–40\text{ mg}$ maintenance.
Indicated in children $\ge 2$ years. IMAgINE 1 Trial established efficacy in pediatric Crohn disease naive or intolerant to infliximab.Maintenance trough concentration $> 7.5–10\ \mu\text{g/mL}$.

2. Next-Generation Biologics and Small Molecules

DrugMechanism of ActionApproved Indications & Advantages in Pediatrics
Vedolizumab (Entyvio)Humanized mAb specifically antagonizing the $\alpha_4\beta_7$ integrin heterodimer, blocking mucosal addressin cell adhesion molecule-1 (MAdCAM-1) binding.Gut-selective mechanism: Blocks T-lymphocyte trafficking into inflamed intestinal tissue without inducing systemic immunosuppression; low risk of opportunistic infections. Highly effective in pediatric UC and CD failing anti-TNF therapy.
Ustekinumab (Stelara)Human IgG1 mAb binding the p40 subunit shared by IL-12 and IL-23, neutralizing Th1 and Th17 inflammatory pathways.Given as weight-based IV loading followed by SC injections every 8–12 weeks. High efficacy in anti-TNF-refractory pediatric Crohn disease; low immunogenicity.
Oral JAK Inhibitors (Upadacitinib, Tofacitinib)Oral small-molecule Janus Kinase inhibitors blocking intracellular cytokine signaling.Rapid onset of action (days); highly effective for acute severe ulcerative colitis or anti-TNF refractory UC in older adolescents.

Safety, Screening, and Monitoring Protocols

  • Pre-Biologic Screening: Mandatory testing for latent tuberculosis (Tuberculin Skin Test / IGRA and Chest Radiography), Hepatitis B surface antigen/anti-HBc, Epstein-Barr Virus (EBV serology), Varicella zoster immunity, and baseline CBC/LFTs.
  • Malignancy and Infection Risks: Infliximab co-administered with thiopurines (azathioprine) carries a rare but fatal risk of Hepatosplenic T-Cell Lymphoma (HSTCL), especially in young adolescent males. Current strategies favor anti-TNF monotherapy combined with proactive TDM optimization, avoiding prolonged combination therapy beyond 6–12 months.